Back to search

Article

Evaluation of Direct susceptibility testing method for Moxifloxacin against Mycobacterium tuberculosis using the BACTEC MGIT 960 system

2026-03-09

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background</h4> Moxifloxacin is a key component of current MDR-TB therapy regimens. The choice to include it in therapy at standard or higher doses is based on the lack or presence of resistance mutations conferring low-level or high-level resistance to moxifloxacin, as detected by the Line probe assay (LPA). Due to inherent phenotypic and genotypic discordance, such resistance must be reco...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
a84b41ad-2592-5feb-ae12-46260ef3b968
DOI
10.64898/2026.03.07.26346296
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Evaluation of Direct susceptibility testing method for Moxifloxacin against Mycobacterium tuberculosis using the BACTEC MGIT 960 systemDOI 10.64898/2026.03.07.26346296
Evaluation of Direct susceptibility testing method for Moxifloxacin against Mycobacterium tuberculosis using the BACTEC MGIT 960 systemSemantic proximity
Exploring Diagnostic Methods for Drug-Resistant Tuberculosis: A Comprehensive OverviewSemantic proximity
Exploring diagnostic methods for drug-resistant tuberculosis: A comprehensive overview.Semantic proximity
Discordant results between Xpert MTB/RIF assay and Bactec MGIT 960 culture system regarding the detection of rifampin-resistant Mycobacterium tuberculosis isolates in Wenzhou, China.Semantic proximity
A cross-sectional study on discordances between Anyplex™ II MTB/MDR and BACTEC MGIT 960 system for assessing susceptibility for Mycobacterium tuberculosis: analysis of clinical specimens from patients with isoniazid-monoresistant, rifampicin-monoresistant, and multidrug-resistant tuberculosis.Semantic proximity
New exploration of the treatment of nontuberculous mycobacterium lung disease: Moxifloxacin may be a first-line drug for the treatment of NTM-PDSemantic proximity
Compact Targeted Next-Generation Sequencing for Rapid Diagnosis of Drug-Resistant Tuberculosis using Minimum BiocontainmentSemantic proximity
Comparative assessment of line probe assays and targeted next-generation sequencing in drug-resistant tuberculosis diagnosisSemantic proximity
Discordance between genotypic and phenotypic methods for the detection of rifampicin and isoniazid resistant Mycobacterium tuberculosis and the correlation with patient treatment outcomesSemantic proximity
MTBDRplus and MTBDRsl for simultaneous diagnosis of gastrointestinal tuberculosis and detection of first-line and second-line drug resistance.Semantic proximity
Rapid diagnosis of drug resistance to fluoroquinolones, amikacin, capreomycin, kanamycin and ethambutol using genotype MTBDRsl assay: a meta-analysis.Semantic proximity
Evaluation of Xpert <sup>®</sup> MTB/XDR test for susceptibility testing of <i>Mycobacterium tuberculosis</i> to first and second-line drugs in UgandaSemantic proximity
Select a neighboring publication to make it the new centre.